Indivior PLC (LON:INDV – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,378.27 ($17.73) and traded as low as GBX 992.57 ($12.77). Indivior shares last traded at GBX 1,047 ($13.47), with a volume of 684,636 shares trading hands.
Analyst Ratings Changes
Separately, Deutsche Bank Aktiengesellschaft dropped their price objective on Indivior from GBX 2,350 ($30.23) to GBX 1,500 ($19.30) and set a “buy” rating for the company in a research note on Tuesday, July 9th.
Read Our Latest Report on Indivior
Indivior Price Performance
Insider Buying and Selling
In other Indivior news, insider Jo Le Couilliard purchased 1,490 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was bought at an average price of GBX 1,006 ($12.94) per share, with a total value of £14,989.40 ($19,281.45). 3.25% of the stock is currently owned by insiders.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- How to Invest in Insurance Companies: A Guide
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Stock Sentiment Analysis: How it Works
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Profitably Trade Stocks at 52-Week Highs
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.